Efficacy of TR 987, Beta-1,3-1,6-D-glucan, in the Treatment of Chronic Venous Insufficiency Ulcers: a Two-arm, Double-blind, Placebo-controlled, Randomized Controlled Trial.

The safety and efficacy of beta glucan products, and specifically TR 987, in the treatment of chronic venous insufficiency ulcers has been established. This study is designed to determine the most efficient method of treatment.

Start Date01 Nov 2016

Sponsor / Collaborator

SerenaGroup, Inc.

[+1]

NCT00792688 / CompletedPhase 2

Double-Blind, Randomized, Placebo-Controlled Phase 2 Study to Investigate the Safety and Efficacy of 0.1% and 1.0% Topically Applied GLYC-101, Compared to Placebo, in Patients Undergoing Carbon Dioxide Laser Skin Resurfacing of the Lower Eyelids.

The primary objectives of this study are to evaluate safety and efficacy of topically applied Glucoprime gel (GLYC-101, 0.1% and GLYC-101, 1.0%) in promoting wound healing in cosmetic surgery patients undergoing Carbon Dioxide Laser Skin Resurfacing (CO2 LSR) of the lower eyelids. The study will observe the effects of the topical agent over the course of 1 month following the initial treatment.

Start Date01 Oct 2008

Sponsor / Collaborator

TR Therapeutics, Inc.

NCT00656474 / CompletedPhase 1/2

Double-blind, Randomized, Placebo-controlled Phase 2 Pilot Study to Investigate the Safety and Clinical Outcomes of 1.0 % Topically Applied GLYC-101, Compared to Placebo, in Healthy Subjects Undergoing Retro-auricular Carbon Dioxide Laser Skin Resurfacing.

Study is intended to evaluate safety and efficacy parameters in patients treated with GLYC-101 gel or placebo after laser ablation.

Start Date01 Mar 2008

Sponsor / Collaborator

TR Therapeutics, Inc.

100 Clinical Results associated with TR-987

100 Translational Medicine associated with TR-987

100 Patents (Medical) associated with TR-987

Literatures (Medical) associated with TR-987

01 May 2011·Wound Repair and RegenerationQ3 · MEDICINE

Particulate β‐glucan induces TNF‐α production in wound macrophages via a redox‐sensitive NF‐κβ‐dependent pathway

Q3 · MEDICINE

Article

Author: Savita Khanna ; Eric Collard ; Sashwati Roy ; Chandan K. Sen ; Urmila Gnyawali ; Gayle M. Gordillo ; Ryan Dickerson

ABSTRACTGlucans are known to promote wound repair. Noncellulosic β‐glucans are recognized as potent immunological activators. β‐Glucans are generally safe and are known to attenuate the rate of postoperative infection. Glyc101 is a particulate β‐glucan isolated from Saccharomyces cerevisiae. In this study, the hypothesis that Glyc101 regulates wound macrophage function was tested. Glyc101 induced tumor necrosis factor (TNF) α transcription in macrophages isolated from murine wound site. Multiplex assay identified interleukin (IL)‐10 and TNFα as two cytokines that are induced by Glyc101 in human blood monocyte‐derived macrophages. Glyc101‐induced TNFα production was observed to be mediated via the TLR‐2 and dectin‐1 receptors, receptor tyrosine kinases and NFκB activation. In murine wound macrophages, Glyc101 potentiated phorbol 12‐myristate 13‐acetate‐induced respiratory burst. In vivo, implantation of Glyc101‐enriched polyvinyl alcohol‐sponges at the wound‐site induced TNFα expression in macrophages. Consistently, Glyc101 induced TNFα expression in wound‐site macrophages isolated from two patients with chronic wounds. These observations establish the translational significance of the net findings of this study. Activation of wound macrophages by Glyc101 represents one of the potential mechanisms by which this β‐glucan may benefit chronic wounds where inefficient inflammatory response is one of the underlying causes of impaired healing.

100 Deals associated with TR-987

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic venous insufficiency	Phase 2	US	TR Therapeutics, Inc.	01 Nov 2016
Varicose Ulcer	Phase 2	-	Kazia Therapeutics Ltd.	-
Wounds and Injuries	Discovery	US	Glycotex, Inc.	01 Mar 2008
Varicose Ulcer	Discovery	AU	TR Therapeutics, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


WCD2023	Phase 2	Chronic venous insufficiency	82	TR987® 0.1% gel	byozvnyyzq(mdwzltzqhh) = yecpwvdqmq nacjuvqdyc (krenfrtclm ) View more	Positive	03 Jul 2023
				Placebo gel	byozvnyyzq(mdwzltzqhh) = fmrforjhmc nacjuvqdyc (krenfrtclm ) View more
NCT00656474 (CTgov)	Phase 1/2	Wounds and Injuries	12	GLYC-101 (GLYC-101 Active Retro-auricular Site (1 Per Participant))	sanompunlt(agpnqqkkxz) = nmfoxcrqaz apkfabykru (qjgmixseeq, ihlenfivvo - nmnngkxjma) View more	-	25 Jul 2011
				Placebo (Placebo Retro-auricular Site (1 Per Participant))	sanompunlt(agpnqqkkxz) = kmvtnfpdmg apkfabykru (qjgmixseeq, vwzysdquap - uabfepkhgv) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

TR-987

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation